Education
About Us
Working with TipRanks
Follow Us
BioLineRX Ltd. (IL:BLRX)
:BLRX
Earnings Data
Report Date
Mar 12, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.33Last Year’s EPS
-0.99Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call highlighted BioLineRx's strategic joint venture for glioblastoma treatment and robust financial health. However, decreased R&D and marketing expenses indicate reduced operational activities following out-licensing agreements. The sentiment is balanced with significant potential in new cancer treatments offset by reduced operational scope.Company Guidance
Joint Venture with Hemispherian
BioLineRx established a joint venture with Hemispherian to develop GLIX1, an innovative molecule for glioblastoma treatment. This partnership leverages BioLineRx's clinical and regulatory success with Hemispherian's expertise in DNA damage response research.
GLIX1 Development and Market Potential
GLIX1, a first-in-class oral molecule, targets DNA damage response in cancer cells. The FDA cleared its IND in August, and a Phase I/IIa trial is planned. The glioblastoma market is expected to be over $3.7 billion in the U.S. and Europe by 2030.
Patent Protection for GLIX1
A notice of allowance for a key patent covering GLIX1 was received, extending protection until 2040. Additional patents cover its use alone and in combination with anticancer agents, ensuring broad protection across multiple regions.
Cash Position and Financial Health
BioLineRx ended the third quarter with $25.2 million in cash, sufficient to fund operations into the first half of 2027. This financial stability is bolstered by potential royalties and milestone-driven revenue.
Positive Results for Motixafortide in Sickle Cell Disease
Final positive results for a Phase I trial of motixafortide in sickle cell disease will be presented at the ASH Annual Meeting. The trial demonstrated robust stem cell mobilization and could expand access to curative treatments for these patients.
IL:BLRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
IL:BLRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 24, 2025 | 1.80 | 1.80 | 0.00% |
Aug 14, 2025 | 2.10 | 2.10 | 0.00% |
May 27, 2025 | 2.20 | 2.00 | -9.09% |
Mar 31, 2025 | 1.90 | 1.90 | 0.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does BioLineRX Ltd. (IL:BLRX) report earnings?
BioLineRX Ltd. (IL:BLRX) is schdueled to report earning on Mar 12, 2026, Before Open (Confirmed).
What is BioLineRX Ltd. (IL:BLRX) earnings time?
BioLineRX Ltd. (IL:BLRX) earnings time is at Mar 12, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of BioLineRX Ltd. stock?
The P/E ratio of Bioline Rx is N/A.
What is IL:BLRX EPS forecast?
IL:BLRX EPS forecast for the fiscal quarter 2025 (Q4) is -0.33.